COVID-19 vaccine patch enters medical institution


HexaPro will likely be delivered the usage of the corporate’s high-density microarray patch (HD-MAP).

Vaxxas holds an unique license from The College of Texas at Austin (UTA) to the SARS-CoV-2 spike subunit vaccine, HexaPro, for vaccination the usage of a patch.

The Segment I scientific trial is being performed in Australia on the College of the Sunshine Coast’s Sippy Downs scientific analysis location.

Below analysis are the security, tolerability, and immunogenicity of the vaccine candidate. The trial will contain 44 wholesome adults, elderly 18 – 50 years inclusive, who’ve had 3 doses of a certified COVID-19 vaccine, with the final dose no less than 4 months previous to collaborating within the learn about.

Along with demonstrating the security of the needle-free vaccine, the trial is designed to collect alerts associated with antibody and T-cell responses to dosing with the patch delivered candidate.

“That is our first trial of this promising vaccine patch. We’re beginning at very low dose without a adjuvants which we all know are used frequently with vaccines to stimulate a better immune reaction,”​ stated Vaxxas CEO, David L Hoey.

“As such, the main endpoint is protection. If the vaccine proves protected, we’ve numerous flexibility to extend the dose or complement the vaccine with an business usual adjuvant and even mRNA shipping at the patch in long run trials if we want or need to power a good better immune reaction.”

Preclinical knowledge

A second-generation SARS-CoV-2 spike protein, HexaPro, is optimized to be efficient in opposition to primary SARS-CoV-2 variants.


Verepass helps sort through the science of COVID-19, process it, and offer an easy pathway to understanding your COVID-19 health, which will get you back to doing what you enjoy.